Update of recent reforms in germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering Drugs

PharmacoEconomics

Volumn 27, Issue 5, 2009, Pages 435-438

  Godman, Brian ^a,b   Schwabe, Ulrich ^c   Selke, Gisbert ^d   Wettermark, Björn ^e,f  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d AOK Research Institute   (Germany)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PROTON PUMP INHIBITOR; SIMVASTATIN;

DRUG COST; DRUG MARKETING; DRUG SAFETY; DRUG UTILIZATION; GERMANY; LETTER; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL;

DRUG COSTS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROTON PUMP INHIBITORS;

EID: 67749120863     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927050-00010     Document Type: Letter

References (30)

1. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoeconomcis Outcomes Res 2008; 8: 357-71
2. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmaco-economics 2008; 26: 537-50
3. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26: 91-8
4. Godman B, Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoeconomcis Outcomes Res 2009; 9: 65-83
5. Beishon J, McBride T. Scharaschkin S. et al. National Audit Office. Prescribing costs in primary care. 14 May 2007 [online]. Available from URL: http://www.nao.org.uk [Accessed 2007 May 21]
6. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008; 1: 497-503
7. Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006; 12: 15-7
8. van Ganse E, Chambea G, Becquart B. et al. France: pharmaceutical pricing and reimbursement information, October 2007 [online]. Available from URL: http:// ppri.oebig.at/Downloads/Results/France-PPRI-2007.pdf [Accessed 2008 Sep 20]
9. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20: 307-28
10. Kanavos P. Generic policies: rhetoric vs reality. Euro Observer 2008; 10: 1-6
11. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 2008; 14: 18-22
12. Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J Generic Med 2006; 4: 4-14
13. Dolezal T. Practical application of PE and HTA in Czech Republic November 2008 [online]. Available from URL: http://www.ceestahc.org/pliki/symp2008/ dolezal.pdf [Accessed 2009 Feb 16]
14. Busse R, Schreyögg J, Henke KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage 2005; 20: 329-49
15. Guidelines for ATC classification and DDD assignment 2006. Oslo: WHO Collaborating Centre for Drug Statistics Methodology [online]. Available from URL: http://www. whocc.no [Accessed 2009 Apr 9]
16. Arzneiverordnungs Report 1999 to 2008. Springer Medizin Verlag Heildelberg [online]. Available from URL: http://www.springer.com/pharma/book/ 978-3-540-69218-8 [Accessed 2009 Jan 19]
17. Wessling A, Lundin D. The review of drugs against disease caused byacid stomach:a summary. Solna: Pharmaceuticals Benefits Board, 2006 [online]. Available from URL: http:// www.tlv.se/upload/genomgangen/summary-stomach-acid. pdf [Accessed 2009 Mar 6]
18. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3
19. Björnsson E, Abrahssom H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945-54
20. Yang YY, Lewis J, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 (24): 2947-53
21. Walley T, Folino-Gallo P, Schwabe U, et al., on behalf of the EuroMedStat Group. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004; 328: 385-6
22. Pfizer criticises SORTIS reference prices: Ministry of Health recommends change. Handelsblatt 2004 Nov 8 [online]. Available from URL: http:\\www.handelsblatt.com/archiv/ pfizer-kritisiert-sortis-festbetrag- ministerium-raet-zum-wechsel; 816275 [Accessed 2009 Jan 19]
23. Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med 2008; 358 (14): 1431-43
24. Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358 (14): 1504-7
25. Alonso PW. Vytorin support statement raises questions over American Heart Association funding. 2008 Jan 24 [online]. Available from URL: http://www.yourlawyer. com/articles/read/13745 [Accessed 2009 May 9]
26. Saul S. Heart group backs drug made by Ally. New York Times 2008 Jan 24 [online]. Available from URL: http:// www.nytimes.com/2008/01/24/business/ 24heart.html?-r=1 [Accessed 2009 May 9]
27. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (13): 1343-56
28. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359 (13): 1357-66
29. Alsheikh-Ali A, Karas R. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. Jn Clinical Lipidology 2009; 3 (2): 138-42
30. Jack A. Balancing big pharma's books. BMJ 2008; 336: 418-9